NEW YORK, May 16 - Genaissance Pharmaceuticals and Prometheus Laboratories have expanded a licensing agreement and plan to collaborate to identify genetic markers, the companies said today.
Prometheus, which licenses a thiopurine S-methyltransferase (TPMT) genetic test from Genaissance, will now be able to use it more broadly. The test assesses a patient's ability to metabolize thiopurine drugs, which are commonly used to treat autoimmune and inflammatory diseases. Genaissance acquired the rights to this test through its purchase of the assets of DNA Sciences.
Prometheus paid Genaissance an upfront fee for the license expansion and will make further payments based on net sales.
In addition, Genaissance and Prometheus plan to collaborate to identify genetic markers that predict patient responses to therapies used to treat gastrointestinal tract diseases as well as autoimmune and inflammatory diseases. Prometheus focuses on these disease areas.